Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Our novel product pipeline addresses areas of high unmet medical need, with a focus on epilepsy.
UPCOMING EVENT NOTICE:
Xenon is hosting its Annual Meeting of Shareholders on June 1, 2022. More event details can be found here.
Read MoreProduct Pipeline
XEN1101
for Adult Focal Epilepsy
X-TOLE Clinical Trial
XEN1101
for Major Depressive Disorder (MDD)
Investigator-led Phase 2 POC study Collaboration with Mount Sinai
XEN1101
for MDD
Company-sponsored Phase 2 POC study
XEN496
for Orphan Pediatric Epilepsy (KCNQ2-DEE)
EPIK Clinical Trial
NBI-921352
for Rare Pediatric Epilepsy: SCN8A-DEE
Partnered with Neurocrine Biosciences
NBI-921352
for Focal-Onset Seizures in Adults
Partnered with Neurocrine Biosciences
PCRX301
for Post-Operative Pain
Partnered with Pacira BioSciences
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
